Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-07-29
1995-09-12
Prescott, Arthur C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
424422, 424424, 424426, 604 19, 604 5, 514824, 128898, A61K 31415, A61K 3140
Patent
active
054496799
ABSTRACT:
Methods and pharmaceutical compositions for reducing the biological fluid level of a lipid soluble waste in a subject are provided. The methods involve selecting a subject diagnosed as having a hyperlipidemia-associated condition and subcutaneously introducing into the subject a biodegradable implant containing a pro-inflammatory lipid that promotes formation of an angiogenic tissue capsule containing a plurality of foam cells. The pro-inflammatory lipid is delivered in an amount sufficient to attain a detectable reduction in the biological fluid level of the lipid soluble waste.
REFERENCES:
patent: 3950529 (1976-04-01), Fisher et al.
patent: 4244945 (1981-01-01), Gupta
patent: 4385732 (1983-05-01), Williams
patent: 4452775 (1983-06-01), Kent
patent: 4532129 (1983-07-01), Comi et al.
patent: 4748024 (1988-05-01), Leonard
patent: 4758569 (1988-07-01), Swindell
patent: 4812441 (1989-03-01), Kawai et al.
patent: 4895558 (1990-01-01), Cham
patent: 4940055 (1990-07-01), Brown
patent: 5110595 (1992-05-01), Wang
patent: 5110738 (1992-05-01), Takano et al.
patent: 5112827 (1992-05-01), Saunders et al.
patent: 5128318 (1992-07-01), Levine et al.
patent: 5192264 (1993-03-01), Fossel
patent: 5196324 (1993-03-01), Bumol et al.
patent: 5208019 (1993-05-01), Hansson et al.
patent: 5281738 (1994-01-01), Parker
patent: 5290549 (1994-03-01), Garnick
Anderson, F. D., et al., "Tissue Response to Bioerodible, Subcutaneous Drug Implants: A Possible Determinant of Drug Absorption Kinetics," Pharmaceutical Research, v. 10, No. 3, pp. 369-380, 1993.
Pataki, M. et al., "Endocytosis of Oxidized LDL and Reversibility of Migration Inhibition in Macrophage-Derived Foam Cells In Vitro--A Mechanism for Atherosclerosis Regression?" Atherosclerosis and Thrombosis, vol. 12, No. 8, pp. 936-944 Aug. 1992.
Stoudemire, J. B., et al., "Effects of Recombinant Human Macrophage Colony-Stimulating Factor on Plasma Cholesterol Levels," Blood, vol. 77, No. 4, pp. 750-755 Feb. 15, 1991.
Levine, D. M., et al., "In vivo protection against endotoxin by plasma high density lipoprotein," Proc. Natl. Acad. Sci. USA vol. 90, pp. 12040-12044, Dec. 1993.
von Baeyer, H., et al., "Covalent coupling of nucleodides to low density lipoprotein (LDL) generates macrophage specific (drug)-carriers," Int'l Journal of Clinical Pharmacology, Therapy and Toxicology, vol. 31, No. 8, pp. 382-386, 1993.
Schultis, H. W., et al., "Preparation of Nucleoside-LDL-Conjugates for the Study of Cell-Selective Internalization: Stability Characteristics and Receptor Affinity," Eur. J. Clin. Chem. Biochem, vol. 29, pp. 665-674, 1991.
Aviram, M., et al., "Serotonin Increases Macrophage Uptake of Oxidized Low Density Lipoprotein," Eur. J. Clin. Chem. Clin. Biochem., vol. 30, pp. 55-61, 1992.
Ravi Subbiah, M. T., et al., "Antioxidant Potential of Specific Estrogens on Lipid Peroxidation," J. Clin. Endocrinology and tabolism, vol. 77, No. 4, pp. 1095-1097, 1993.
Kita, T., et al., "The Role of Oxidized Lipoproteins in the Pathogenesis of Atherosclerosis," Clinical and Experimental Pharmacology and Physiology, vol. 19, pp. 37-42, 1992.
Fuhrman, B., et al., "Proteins derived from platelet .alpha. granules modulate the uptake of oxidized low density lipoprotein by macrophages," Biochimica et Biophysica Acta, vol. 1127, pp. 15-21, 1992.
Vilella, E., et al., "Interaction of oxidized low density lipoproteins with both apo B, E and scavenger receptors. A model for its production in vitro," Clinica Chimica Acta, vol. 210, pp. 93-108, 1992.
Maziere, C., et al., "Estrogens inhibit copper and cell-mediated modification of low density lipoprotein," Atherosclerosis, vol. 89 pp. 175-182, 1991.
Reid, V. C., et al., "Toxicity of oxidised low density lipoprotein towards mouse peritoneal macrophages in vitro," Atherosclerosis, vol. 98, pp. 17-24, 1993.
Yamada, N., et al., "Role of Monocyte Colony-Stimulating Factor in Cell Generation," M-CSF and Atherosclerosis, pp. 240-244, 1992.
Ku, G., et al., "Induction of Interleukin a.beta. Expression from Human Peropheral Blood Monocyte-derived Macrophages by 9-Hydroxyoctadecadienoic Acid," Journal of Biological Chemistry, vol. 267, No. 20, pp. 14183-14188, 1992.
Zioncheck, T. F., et al., "Interaction of Recombinant Apolipoprotein(a) and Lipoprotein(a) with Macrophages," J. Clin. Invest., vol. 887, pp. 767-771, Mar. 1991.
Srinivasan, S. R., et al., "Proteoglycans, Lipoproteins, and Atherosclerosis," Hypercholesterolemia, Hypocholesterolemia, Hypertriglyceridemia, Plenum Press, New York, pp. 373-381, 1990.
Hara, S., et al., "Probucol Pretreatment Enhances the Chemotaxis of Mouse Peritoneal Macrophages," Arteriosclerosis and Thrombosis, vol. 12, No. 5, pp. 593-600, May 1992.
Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 1990, Pergamon Press, Inc., pp. 874-876.
LandOfFree
Process and products for reducing biological fluid levels of a l does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process and products for reducing biological fluid levels of a l, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process and products for reducing biological fluid levels of a l will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-405466